20 Oct 2021 COUR Pharmaceuticals Announces First in Human Dosing in Proof-of-Concept Trial of CNP-201 to Treat Peanut Allergy
18 Oct 2021 Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
16 Oct 2021 Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the Safety and Immunogenicity of Its Single-Dose Chikungunya Vaccine Candidate, CHIKV VLP
13 Oct 2021 Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer
13 Oct 2021 Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
13 Oct 2021 First Patient Dosed With PVSRIPO in Istari Oncology’s LUMINOS-103 Phase 1/2 Bladder Cancer Sub-Study
13 Oct 2021 CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology
07 Oct 2021 Imophoron raises GBP 4 million funding for rapid vaccine development
07 Oct 2021 GSK welcomes WHO recommendation for broad roll-out of its RTS,S/AS01e (RTS,S) malaria vaccine
06 Oct 2021 Vaxart Begins Recruiting in Global Phase II COVID-19 Oral Tablet Vaccine Clinical Trial
06 Oct 2021 Moderna Announces European Medicines Agency Authorizes Third Dose of COVID-19 Vaccine for Immunocompromised Individuals Aged 12 Years and Older
05 Oct 2021 Johnson & Johnson Announces Submission of Emergency Use Authorization Amendment to the U.S. FDA to Support Booster of its Single-Shot COVID-19 Vaccine
04 Oct 2021 Pfizer and BioNTech Receive CHMP Positive Opinion for COVID-19 Vaccine Booster in the European Union
04 Oct 2021 Janssen Announces Phase 2b Data Demonstrating its Investigational RSV Adult Vaccine Provided 80% Protection Against Lower Respiratory Infections in Older Adults
01 Oct 2021 BioNTech Expands Clinical Oncology Portfolio with First Patient Dosed in Phase 2 Trial of mRNA-based Individualized Immunotherapy BNT122 in Colorectal Cancer Patients
28 Sep 2021 Sanofi to focus its COVID-19 development efforts on the recombinant vaccine candidate
28 Sep 2021 Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate
27 Sep 2021 CyanVac and Blue Lake Biotechnology Announce First Participant Dosed in a Phase 1 Clinical Trial to Evaluate its CVXGA1 Intranasal COVID-19 Vaccine
23 Sep 2021 Elicio Therapeutics Presents Updated Preclinical Data at the 2021 Vaccines Summit Demonstrating that ELI-005, a Lymph Node Targeted Amphiphile Vaccine, Induces Potent Cellular and Humoral Immunity to SARS-CoV-2
23 Sep 2021 Clover’s COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest
23 Sep 2021 Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine Booster
22 Sep 2021 Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.
20 Sep 2021 Gritstone Announces Dosing of First Volunteer in Trial Evaluating Self-Amplifying mRNA as a COVID-19 Vaccine Booster and Immunogenicity Enhancer
20 Sep 2021 Pfizer and BioNTech Announce Positive Topline Results from Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years
18 Sep 2021 Gritstone Announces Dosing of First Solid Tumor Patient with Optimized SLATE “Off-the-Shelf” Mutant KRAS-directed Neoantigen Immunotherapy in Phase 2 Clinical Trial

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up